InvestSMART

Paradigm Biopharmaceuticals Limited (ASX: PAR) - Announcements

Current share price for PAR : $0.210 0.01 (5%)+

ASX company news and announcements for Paradigm Biopharmaceuticals Limited (PAR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Paradigm Biopharmaceuticals Limited (PAR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Paradigm Biopharmaceuticals Limited (PAR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Paradigm Biopharmaceuticals Limited (PAR)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$127 Quarterly Update and Appendix 4C - quarterly 28 Apr 2020 8:41AM $1.495 $0.210 fallen by 85.95%
$127 Cleansing Notice and Appendix 2A 16 Apr 2020 9:29AM $1.770 $0.210 fallen by 88.14%
$127 Reinstatement to Official Quotation 8 Apr 2020 12:23PM $1.690 $0.210 fallen by 87.57%
$127 Paradigm completes $35m raising 8 Apr 2020 12:23PM $1.690 $0.210 fallen by 87.57%
$127 Proposed issue of Securities - PAR 8 Apr 2020 10:52AM $1.690 $0.210 fallen by 87.57%
$127 PARADIGM TO HOST INVESTOR CALL 7 Apr 2020 3:49PM $1.690 $0.210 fallen by 87.57%
$127 Paradigm Reports Very Encouraging Real World Data 6 Apr 2020 1:07PM $1.690 $0.210 fallen by 87.57%
$127 Paradigm receives clarity on US regulatory pathway 6 Apr 2020 12:48PM $1.690 $0.210 fallen by 87.57%
$127 Paradigm Latest Corporate Presentation 6 Apr 2020 12:21PM $1.690 $0.210 fallen by 87.57%
$127 Voluntary Suspension 6 Apr 2020 11:54AM $1.690 $0.210 fallen by 87.57%
$127 Trading Halt 2 Apr 2020 9:21AM $1.690 $0.210 fallen by 87.57%
$127 Appendix 3G 24 Mar 2020 4:37PM $1.630 $0.210 fallen by 87.12%
$127 Paradigm to present at Virtual Conference, Friday 27th March 24 Mar 2020 8:38AM $1.205 $0.210 fallen by 82.57%
$127 All 10 participants in US FDA EAP have commenced treatment 24 Mar 2020 8:22AM $1.205 $0.210 fallen by 82.57%
$127 Change in substantial holding 16 Mar 2020 1:51PM $1.620 $0.210 fallen by 87.04%
$127 Change of Director's Interest Notice 16 Mar 2020 1:48PM $1.640 $0.210 fallen by 87.20%
$127 Appendix 3B and Appendix 3G 28 Feb 2020 4:35PM $2.850 $0.210 fallen by 92.63%
$127 Paradigm reports Positive Pre-IND meeting with US FDA 21 Feb 2020 8:16AM $3.670 $0.210 fallen by 94.28%
$127 Paradigm - first patient dosed in USA under FDA approved EAP 18 Feb 2020 9:12AM $4.120 $0.210 fallen by 94.90%
$127 Half Yearly Report and Accounts 14 Feb 2020 4:27PM $4.170 $0.210 fallen by 94.96%
$127 Paradigm presents MPS VI poster at WORLD Symposium 13 Feb 2020 8:28AM $4.350 $0.210 fallen by 95.17%
$127 Cleansing Notice and Appendix 2A 10 Feb 2020 5:17PM $4.160 $0.210 fallen by 94.95%
$127 Cleansing Notice and Appendix 2A 3 Feb 2020 4:40PM $4.030 $0.210 fallen by 94.79%
$127 Quarterly Update and Appendix 4C - quarterly 31 Jan 2020 2:42PM $4.190 $0.210 fallen by 94.99%
$127 Updated Appendix 2A 15 Jan 2020 4:18PM $3.730 $0.210 fallen by 94.37%

451 - 475 of 724 results

Page 19 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.